Mechanisms in progestin antagonism of pituitary tumorigenesis.
Chronic exposure of F344 rats to diethylstilbestrol (DES) induces pituitary tumors (DES-T) composed of proliferating lactotrophs. Presently, we studied the effect of progestins on parameters related to tumor growth and function, due to previous evidences of progesterone antagonism of pituitary tumorigenesis acting at pituitary and hypothalamic levels [Piroli, G., Grillo, C., Ferrini, M., Lux-Lantos, V. and De Nicola, A. F., Antagonism by progesterone of diethylstilbestrol-induced pituitary tumorigenesis in Fischer 344 rats: Effects on sex steroid receptors and tyrosine hydroxylase mRNA, Neuroendocrinology, 1996, 63, 530-539]. In search of a quantitatively more important effect, animals bearing DES-T were treated with synthetic progestins. Competition assays using DES-T as source of progestin receptors indicated that levonorgestrel (LNG), gestodene and R5020 showed higher affinities (IC50 1-2 nM) than progesterone, norethisterone and medroxyprogesterone (IC50 10-25 nM). Treatment with LNG reduced DES-T weight by 45%, and serum PRL by one half. Small (monomeric) and big (polymeric) PRL increased 5- and 2.5-fold, respectively, in DES-T in comparison with pituitaries of ovariectomized (OVX) rats. However, LNG produced no changes indicating that synthesis and storage of PRL was conserved in rats receiving both hormonal treatments. DES induced a 15-fold increase in cell proliferation, measured as bromodeoxyuridine incorporation into cell nuclei, in comparison to OVX rats, while LNG treatment of DES-T bearing rats reduced this index by 72%. Electron microscopic images showed that LNG markedly reduced hypertrophy and hyperplasia of lactotropes, increasing the proportions of degenerating cells and cells of high electronic density with alterations of cytoplasmic organelles. However, histopathological signs of apoptosis were absent. Therefore, reduced cell proliferation and non-apoptotic cell death are part of the mechanisms employed by progestins to antagonize tumorigenesis at the pituitary level. The results may open a new therapeutic strategy for treatment of PRL secreting adenoma in humans.
Piroli
G
G
Instituto de Biología y Medicina Experimental, Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Torres
A
A
Grillo
C
C
Lux-Lantos
V
V
Aoki
A
A
De Nicola
A F
AF
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D004054:Diethylstilbestrol / Q000633:toxicity; D005260:Female; D016912:Levonorgestrel / Q000378:metabolism / Q000494:pharmacology; D008854:Microscopy, Electron; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D010052:Ovariectomy; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D010911:Pituitary Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D045167:Progesterone Congeners / Q000378:metabolism / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
D045167:Progesterone Congeners; D016912:Levonorgestrel; D004054:Diethylstilbestrol; D011388:Prolactin